In addition to cancer research, tissue arrays are increasingly used in studying a wide range of diseases such as cardiovascular disorders, neurological conditions, infectious diseases, and inflammatory processes. By including normal, diseased, and treated tissue samples within a single array, scientists can investigate pathological mechanisms and therapeutic effects in a controlled, comparative framework. For example, in neuroscience, tissue arrays have been utilized to explore protein expression in brain tissues affected by Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions. Similarly, in immunology, arrays help researchers study immune responses in tissues infected by viruses or bacteria, allowing for simultaneous assessment of cytokine expression or immune cell infiltration. The versatility of tissue arrays extends to pharmacological research as well, where drug efficacy and toxicity can be evaluated across different tissue types using the same experimental setup. This application is particularly valuable in preclinical testing, where rapid and cost-effective screening of candidate drugs is essential.
One of the key strengths of tissue arrays lies in their compatibility with multiple molecular analysis techniques beyond traditional histopathology. In addition to immunohistochemistry, tissue arrays can be used for in situ hybridization (ISH), fluorescence in situ hybridization (FISH), and even next-generation sequencing (NGS)-based assays, depending on the preservation quality of nucleic acids within the paraffin-embedded samples. This flexibility allows researchers to assess not only protein expression but also DNA mutations, RNA rare cancer tissue microarray , and epigenetic modifications in a spatially preserved tissue context. For example, FISH assays performed on tissue arrays can identify chromosomal aberrations, gene amplifications, or translocations across hundreds of samples in a single experiment. Similarly, RNA in situ hybridization enables visualization of gene expression patterns within tissue architecture, providing valuable information about the localization of specific transcripts. The integration of these molecular techniques with tissue array platforms supports comprehensive, multidimensional analyses that bridge histopathological and genomic data, enhancing our understanding of disease biology.
Despite their numerous advantages, tissue arrays also come with certain limitations that must be acknowledged. One concern is the issue of tissue heterogeneity, particularly in tumors where different regions may exhibit variable cellular composition and molecular characteristics. Since tissue cores represent only a small portion of the donor block, they may not capture the full diversity of the tissue’s pathological features. To address this, researchers often include multiple cores from different regions of the same specimen to improve representativeness. Another limitation relates to the potential loss of antigenicity or nucleic acid integrity in archived samples, especially those that have been stored for long periods. Proper storage and handling of FFPE tissues are crucial to ensure reliable results. Additionally, the technical precision required in constructing arrays can pose challenges; slight misalignment during embedding or sectioning may lead to data inconsistencies. Despite these issues, advances in automated arrayers and digital pathology systems have significantly improved the accuracy and reproducibility of tissue array construction and analysis.
Digital pathology and artificial intelligence (AI) have further enhanced the utility of tissue arrays in modern biomedical research. High-resolution scanning of tissue array slides enables digital image analysis, which allows for objective quantification of staining intensity, cellular morphology, and spatial relationships between biomarkers. AI-powered algorithms can rapidly analyze thousands of tissue cores and extract meaningful data patterns that might be overlooked by human observers. This combination of tissue array technology and computational pathology has opened new avenues for biomarker discovery and validation. For instance, deep learning models can be trained on tissue array datasets to predict disease outcomes or classify tumor subtypes based on morphological and molecular signatures. These innovations not only increase the efficiency of analysis but also improve diagnostic precision and reproducibility in research and clinical settings.